Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082707 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL8438785 | 0.86 | TDP1 (0.59) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL10037268 | 0.86 | TDP1 (0.50) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL25014915 | 0.86 | TDP1 (0.50) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL14646688 | 0.86 | TDP1 (0.50) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL1584489 | 0.84 | TDP1 (0.49) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL12103908 | 0.84 | TDP1 (0.49) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL903325 | 0.84 | TDP1 (0.49) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL14755649 | 0.84 | TDP1 (0.49) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL1785039 | 0.84 | MEN1 (0.50) | TDP1MEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-20260015378-A1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (KY) | 2026-01-15 | — | — | US | disclosed |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| EP-4605426-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025081282-A1 | ANTI-NAPI2B ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-04-24 | — | — | WO | disclosed |
| US-12258368-B2 | Disulfide-linked reversible terminators | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (KY) | 2025-03-25 | — | — | US | disclosed |
| EP-2266623-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266625-A2 | Prodrugs Containing Novel Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266622-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-1789091-B1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LTD (IN) | 2010-08-25 | — | — | EP | disclosed |
| EP-2075011-A2 | Prodrugs Containing Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| EP-2075011-A2 | Prodrugs Containing Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| EP-1789091-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | Nicholas Piramal India Limited (IN) | 2007-05-30 | — | — | EP | disclosed |
| US-20060205674-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | NICHOLAS PIRAMAL INDIA LTD. (IN) | 2006-09-14 | — | — | US | disclosed |
| WO-2006027711-A2 | PRODRUGS AND CODRUGS CONTAINING BIO- CLEAVABLE DISULFIDE LINKERS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
| US-20060046967-A1 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited (IN) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | TDP1 2708/4885MEN1 2231/4885KMT2A 2538/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | TDP1 2708/4885MEN1 2231/4885KMT2A 2538/4885 |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | SLC34A2, SLC20A2, SLC34A1 | TDP1 2024/4885MEN1 1723/4885KMT2A 3039/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | TDP1 2927/4885MEN1 1426/4885KMT2A 3934/4885 |
| US-20260015378-A1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | RNGTT, NSUN2, NSUN3 | TDP1 131/4885MEN1 4741/4885KMT2A 2716/4885 |
| US-20060046967-A1 | Prodrugs containing novel bio-cleavable linkers | SI, UGT1A1, CYP2B6 | TDP1 1074/4885MEN1 1169/4885KMT2A 4238/4885 |
| US-12258368-B2 | Disulfide-linked reversible terminators | RNGTT, NSUN2, NSUN3 | TDP1 374/4885MEN1 4765/4885KMT2A 2855/4885 |
| US-20060205674-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | SI, UGT1A1, PAICS | TDP1 515/4885MEN1 1469/4885KMT2A 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.